Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    9808548 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed R-ICE (ICE Plus Rituximab) Versus R-DHAP (DHAP Plus Rituximab) in Patients Aged 18-65 With Relapse Diffuse Large B-Cell Lymphoma
Condition: Lymphoma, Large-Cell, Diffuse
Interventions: Drug: DHAP plus rituximab;   Drug: ICE plus rituximab

Indicates status has not been verified in more than two years